Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Neuropsychiatric side effects after the use of mefloquine.

Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD.

Am J Trop Med Hyg. 1991 Jul;45(1):86-91.

PMID:
1867351
2.

[Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].

Minei-Rachmilewitz T.

Harefuah. 1999 Jul;137(1-2):25-7, 87. Hebrew.

PMID:
10959270
3.

[Neuropsychiatric symptoms caused by mefloquine (report of several cases)].

Murai Z, Baran B, Tolna J, Szily E, Gazdag G.

Orv Hetil. 2005 Jan 16;146(3):133-6. Hungarian.

PMID:
15693445
4.
5.

[Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].

Lebain P, Juliard C, Davy JP, Dollfus S.

Encephale. 2000 Jul-Aug;26(4):67-70. French.

PMID:
11064842
6.
7.

[Mefloquine: neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug].

Jensen JJ.

Ugeskr Laeger. 1998 Apr 13;160(16):2413. Danish. No abstract available.

PMID:
9616091
8.

Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine.

Hennequin C, Bourée P, Bazin N, Bisaro F, Feline A.

Arch Intern Med. 1994 Oct 24;154(20):2360-2.

PMID:
7944858
9.

Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine.

Clattenburg RN, Donnelly CL.

J Am Acad Child Adolesc Psychiatry. 1997 Nov;36(11):1606-8.

PMID:
9394947
10.

Paranoid psychosis related to mefloquine antimalarial prophylaxis.

Fuller SJ, Naraqi S, Gilessi G.

P N G Med J. 2002 Sep-Dec;45(3-4):219-21.

PMID:
12968793
11.
12.

Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions.

Bem JL, Kerr L, Stuerchler D.

J Trop Med Hyg. 1992 Jun;95(3):167-79.

PMID:
1597872
13.

MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.

Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP, Stricker BH.

Clin Pharmacol Ther. 2006 Oct;80(4):367-74.

PMID:
17015054
14.

Neuropsychiatric events during prophylactic use of mefloquine before travelling.

van Riemsdijk MM, Ditters JM, Sturkenboom MC, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH.

Eur J Clin Pharmacol. 2002 Sep;58(6):441-5. Epub 2002 Jul 27.

PMID:
12242605
15.

[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].

Oueriagli Nabih F, Touhami M, Laffinti A, Abilkacem L.

Encephale. 2011 Oct;37(5):393-6. doi: 10.1016/j.encep.2011.01.013. Epub 2011 Mar 25. French.

PMID:
22032283
16.

Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands.

van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH.

J Clin Psychiatry. 2005 Feb;66(2):199-204.

PMID:
15705005
17.

Mefloquine-induced pneumonitis.

Soentjens P, Delanote M, Van Gompel A.

J Travel Med. 2006 May-Jun;13(3):172-4.

18.

Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis.

Hoebe C, de Munter J, Thijs C.

Eur J Clin Pharmacol. 1997;52(4):269-75.

PMID:
9248763
19.

Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.

Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG.

Am J Trop Med Hyg. 1996;55(1 Suppl):50-6.

PMID:
8702037
20.

Side effects of and compliance with malaria prophylaxis in children.

Albright TA, Binns HJ, Katz BZ.

J Travel Med. 2002 Nov-Dec;9(6):289-92.

Supplemental Content

Support Center